Avistone has built a portfolio of globally competitive drug pipelines targeting cancers with substantial unmet clinical needs. We welcome collaboration from major pharmaceutical companies, healthcare investment institutions, and other partners to advance the overseas rights development of these pipelines. Avistone is committed to allocating robust resources to the overseas development of its products, ensuring both efficiency and success in their advancement. We aim to contribute to our partners' success while bringing benefits to patients worldwide. For more details on Avistone's drug pipelines, please visit our pipeline page.

Avistone boasts seasoned teams specializing in early-stage drug discovery and clinical operations across China and the United States. With deep expertise in molecular design and clinical development of innovative therapeutics, the company has successfully completed early R&D of multiple novel drug molecules, as well as clinical trials in both territories. Notably, for Vebreltinib, Avistone’s team has advanced three indications to development success, two of which are global first-in-class.

Avistone possesses proven experience and a systematic platform spanning the entire product lifecycle—encompassing molecular design, CMC (Chemistry, Manufacturing and Controls) development, multi-regional clinical trials, regulatory filing, and commercialization. We welcome partners with globally leading preclinical candidate (PCC)-stage molecules to establish effective collaborations, aiming to co-develop oncology therapeutics that deliver greater benefits to patients worldwide.

Avistone has built an elite commercialization team of several hundred professionals across China, successfully spearheading Vebreltinib's market launch, inclusion in China's National Reimbursement Drug List (NRDL), brand building, and academic promotion efforts.

Proficient in aligning with the latest industry trends, Avistone's commercialization team leverages deep professional expertise to execute impactful initiatives. We welcome excellent partners with leading oncology drugs—whether already launched or soon-to-be launched in China—to collaborate with us.